Biodexa Pharmaceuticals (BDRX) News Today $1.59 -0.16 (-9.14%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.62 +0.02 (+1.57%) As of 03/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Promising Nanotechnology Stocks To Watch Now - March 19thBiodexa Pharmaceuticals, OSI Systems, Virpax Pharmaceuticals, NVE, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares in companies that focus on developing and commercializing technologies at the nanosMarch 20, 2025 | marketbeat.comBiodexa says on track to initiate Phase 3 trial in FAP next quarterMarch 20, 2025 | markets.businessinsider.comShort Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Declines By 23.2%Biodexa Pharmaceuticals Plc (NASDAQ:BDRX - Get Free Report) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 36,100 shares, a decline of 23.2% from the February 13th total of 47,000 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 830,300 shares, the days-to-cover ratio is currently 0.0 days.March 17, 2025 | marketbeat.comBiodexa Pharmaceuticals PLC Achieves Key Milestone with FDA Following Type C Meeting for Phase 3 eRapa Study in Familial Adenomatous PolyposisMarch 12, 2025 | nasdaq.comBiodexa Pharma To Initiate Registrational Phase 3 Study Of ERapa In FAP In Next QuarterMarch 12, 2025 | nasdaq.comBest Nanotechnology Stocks To Consider - March 10thBiodexa Pharmaceuticals, OSI Systems, NVE, Virpax Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies that research, develop, and manufacture products using nanoscale technMarch 11, 2025 | marketbeat.comBiodexa Pharmaceuticals PLC: Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPMarch 10, 2025 | finanznachrichten.deBiodexa Pharmaceuticals announces outcome of a Type C meeting with FDA on eRapaMarch 10, 2025 | markets.businessinsider.comBiodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPMarch 10, 2025 | globenewswire.comBiodexa Pharmaceuticals announces appointment of Precision for Medicine as CROMarch 6, 2025 | markets.businessinsider.comBiodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAPMarch 6, 2025 | globenewswire.comBiodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Large Increase in Short InterestBiodexa Pharmaceuticals Plc (NASDAQ:BDRX - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 47,000 shares, an increase of 1,368.8% from the January 31st total of 3,200 shares. Based on an average daily volume of 512,200 shares, the days-to-cover ratio is presently 0.1 days.February 28, 2025 | marketbeat.comBiodexa Pharmaceuticals PLC: Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and UseFebruary 24, 2025 | finanznachrichten.deBiodexa Pharmaceuticals announces allowance of U.S. patent covering eRapaFebruary 24, 2025 | markets.businessinsider.comBiodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and UseFebruary 24, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025February 13, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track StatusFebruary 12, 2025 | finanznachrichten.deBiodexa Pharmaceuticals receives Fast Track designation for eRapaFebruary 12, 2025 | markets.businessinsider.comBiodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track DesignationFebruary 11, 2025 | marketwatch.comBiodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisFebruary 10, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC: Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical OfficerJanuary 24, 2025 | finanznachrichten.deBiodexa Pharmaceuticals Names Gary Shangold Chief Medical Officer - Quick FactsJanuary 22, 2025 | markets.businessinsider.comBiodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical OfficerJanuary 22, 2025 | globenewswire.comBiodexa Pharmaceuticals files to sell 35.875M ADS for holdersJanuary 17, 2025 | markets.businessinsider.comBiodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the UpgradeJanuary 4, 2025 | msn.comBiodexa Pharmaceuticals Adjusts Share Value Amid Drug Development FocusDecember 5, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals announces result of general meetingNovember 23, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals PLC: Result of General MeetingNovember 22, 2024 | finanznachrichten.deResult of General MeetingNovember 22, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXNovember 18, 2024 | prnewswire.comBiodexa Pharmaceuticals Secures Nasdaq Listing ComplianceNovember 13, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals regains Nasdaq complianceNovember 13, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on NasdaqNovember 12, 2024 | globenewswire.comBiodexa Pharmaceuticals Plans Strategic Share Value AdjustmentNovember 9, 2024 | markets.businessinsider.comNotice of General MeetingNovember 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXNovember 2, 2024 | prnewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 29, 2024 | globenewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 28, 2024 | businesswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXOctober 25, 2024 | prnewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 23, 2024 | globenewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 20, 2024 | businesswire.comBiodexa ADRs Rise After Successful Appeal of Nasdaq DelistingOctober 17, 2024 | marketwatch.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXOctober 17, 2024 | prnewswire.comLost Money on Biodexa Pharmaceuticals Plc (BDRX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationOctober 16, 2024 | stockhouse.comBiodexa Pharmaceuticals PLC: Biodexa Announces Successful Appeal of Nasdaq DelistingOctober 16, 2024 | finanznachrichten.deBiodexa Pharmaceuticals Stock Is Soaring After The Close: What's Driving Shares Higher?October 16, 2024 | benzinga.comBiodexa Announces Successful Appeal of Nasdaq DelistingOctober 15, 2024 | globenewswire.comFreightCar America (NASDAQ:RAIL) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comBiodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.com Remove Ads Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BDRX Media Mentions By Week BDRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDRX News Sentiment▼0.200.79▲Average Medical News Sentiment BDRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDRX Articles This Week▼31▲BDRX Articles Average Week Remove Ads Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Esperion Therapeutics News Today ProKidney News Today Corvus Pharmaceuticals News Today Alpha Teknova News Today Annexon News Today MBX Biosciences News Today Candel Therapeutics News Today Aquestive Therapeutics News Today Septerna News Today iTeos Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDRX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
